China Pharma Q2 FY26 net loss widens to $1.46 million; revenue falls 7.77% to $0.95 million

The company closed a $5 million common-stock sale at $2 per share in July 2026, generating net proceeds of $4.43 million.

China Pharma posted a net loss of $2.6 million for the six months ended June 30, 2026, widening from $1.31 million.

Revenue fell 10.6% to $1.93 million, with CNS cerebral and cardiovascular sales rising to $1.02 million.

Gross profit swung to $0.37 million from a gross loss of $0.22 million, lifting gross margin to 19.1% from -10.3%.

Operating loss widened to $2.55 million from $1.41 million on higher amortization tied to five patented technology acquisitions since August 2025.